UBS Boosts Bristol-Myers Squibb (BMY) Price Target as Milvexian Data Looms

UBS has raised its price target for Bristol-Myers Squibb (BMY) in anticipation of upcoming data on Milvexian, a novel anticoagulant medication. This positive outlook reflects UBS's confidence in the drug's potential to enhance BMY's portfolio. The market responded favorably to this news, leading to an uptick in BMY's stock price. Investors are encouraged to keep an eye on the impending data release for Milvexian, which could further influence stock performance. Overall, this move indicates a bullish sentiment toward BMY's future prospects.